Theravance Biopharma (TBPH) Enterprise Value (2014 - 2026)

Theravance Biopharma (TBPH) has 13 years of Enterprise Value data on file, last reported at -$394.7 million in Q1 2026.

• On a quarterly basis, Enterprise Value fell 201.61% year-over-year to -$394.7 million in Q1 2026; TTM through Mar 2026 was -$394.7 million, a 201.61% decrease from a year earlier, with the FY2025 full-year figure at -$315.4 million, down 256.94% from the prior year.
• Enterprise Value for Q1 2026 stood at -$394.7 million, down from -$315.4 million in the prior quarter.
• Over the last five years, Enterprise Value for TBPH reached as high as -$88.4 million in Q4 2024 and fell as low as -$486.8 million in Q3 2022.
• Historically, Enterprise Value has averaged -$213.2 million across 5 years, with a median of -$147.5 million in 2022.
• Across the five-year window, Enterprise Value soared 72.47% in 2023 and sank 260.85% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$327.5 million in 2022, then surged by 68.72% to -$102.4 million in 2023, then increased by 13.74% to -$88.4 million in 2024, then sank by 256.94% to -$315.4 million in 2025, then dropped by 25.15% to -$394.7 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$394.7 million in Q1 2026, -$315.4 million in Q4 2025, and -$329.7 million in Q3 2025.